Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$0.25 - $11.7 $979 - $45,817
-3,916 Closed
0 $0
Q2 2022

Aug 22, 2022

SELL
$0.3 - $1.31 $227 - $994
-759 Reduced 16.24%
3,916 $1,000
Q4 2021

Feb 14, 2022

SELL
$1.16 - $2.74 $91,967 - $217,232
-79,282 Reduced 94.43%
4,675 $6,000
Q3 2021

Nov 15, 2021

BUY
$2.62 - $5.43 $181,948 - $377,091
69,446 Added 478.57%
83,957 $220,000
Q2 2021

Aug 12, 2021

BUY
$5.06 - $8.15 $430 - $692
85 Added 0.59%
14,511 $77,000
Q1 2021

May 17, 2021

SELL
$6.24 - $9.58 $1,747 - $2,682
-280 Reduced 1.9%
14,426 $97,000
Q3 2020

Nov 13, 2020

SELL
$7.5 - $11.11 $12,525 - $18,553
-1,670 Reduced 10.2%
14,706 $111,000
Q2 2020

Aug 14, 2020

BUY
$8.33 - $13.79 $108,456 - $179,545
13,020 Added 387.96%
16,376 $172,000
Q1 2020

May 14, 2020

SELL
$3.83 - $8.79 $4,634 - $10,635
-1,210 Reduced 26.5%
3,356 $30,000
Q4 2019

Feb 13, 2020

BUY
$3.36 - $4.81 $1,394 - $1,996
415 Added 10.0%
4,566 $17,000
Q2 2019

Aug 14, 2019

BUY
$4.93 - $8.8 $6,872 - $12,267
1,394 Added 50.56%
4,151 $27,000
Q1 2019

May 15, 2019

BUY
$5.19 - $8.97 $4,157 - $7,184
801 Added 40.95%
2,757 $23,000
Q2 2018

Aug 10, 2018

SELL
$13.3 - $17.49 $7,315 - $9,619
-550 Reduced 21.95%
1,956 $27,000
Q1 2018

May 17, 2018

BUY
$12.26 - $18.98 $8,079 - $12,507
659 Added 35.68%
2,506 $40,000
Q4 2017

Feb 13, 2018

BUY
$13.68 - $23.17 $25,266 - $42,794
1,847
1,847 $35,000

Others Institutions Holding KALA

# of Institutions
1
Shares Held
1
Call Options Held
0
Put Options Held
0

About Kala Pharmaceuticals, Inc.


  • Ticker KALA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 1,464,160
  • Market Cap $9.05M
  • Description
  • Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent...
More about KALA
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.